Observational studyScientific reports2025
Biomarkers of cell cycle arrest, microcirculation dysfunction, and inflammation in the prediction of SA-AKI.
Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The LINC00920/miR-6834-3p/CPN1 Axis Modulates Immune Dysregulation in Sepsis-Associated Acute Kidney Injury and Serves as a Diagnostic Biomarker.Biochemical genetics · 2026Article
- Beyond eGFR and Albuminuria: Biological Pathways and Multiomics in Cardiovascular-Kidney-Metabolic Disease.Kidney international reports · 2026Review
- Review of research progress in sepsis-associated acute kidney injury.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Sepsis-associated acute kidney injury (SA-AKI) is a severe complication in critically ill patients, with a complex pathogenesis involving in cell cycle arrest, microcirculatory dysfunction, and inflammation. Current diagnostic strategies remain suboptimal. Therefore, this study aimed to evaluate pathophysiology-based biomarkers and develop an improved predictive model for SA-AKI. The prospective observational study was conducted, enrolling 26 healthy individuals and 96 sepsis patients from Peking University Third Hospital. Clinical and laboratory data were collected, and patients were monitored for AKI development within 72 h. Further, sepsis patients were categorized into SA-noAKI (n = 46) and SA-AKI (n = 50) groups. Novel biomarkers, including tissue inhibitor of metalloproteinase-2 (TIMP-2), insulin-like growth factor-binding protein-7 (IGFBP-7), and angiopoietin-2 (Ang-2), were measured in all participants. Among these sepsis patients, the SA-AKI incidence was 52.08% (50/96). Compared to SA-noAKI, the SA-AKI group had significantly higher levels of TIMP-2 (93.55 [79.36, 119.56] ng/mL), IGFBP-7 (27.8 [21.44, 37.29] ng/mL), TIMP-2×IGFBP-7 (2.91 [1.90, 3.55] (ng/mL)²/1000), and Ang-2 (10.61 [5.79, 14.57] ng/mL) (P < 0.05). Accordingly, logistic regression identified TIMP-2×IGFBP-7 (OR = 2.71), Ang-2 (OR = 1.19), and PCT (OR = 1.05) as independent risk factors. The ROC curve of the predictive model demonstrated superior early-stage accuracy (AUC = 0.898), which remained stable during internal validation (AUC = 0.899). Meanwhile, the nomogram exhibited that this model was characterized with excellent discrimination, calibration, and clinical performance. In general, TIMP-2×IGFBP-7, Ang-2 and PCT were the independent risk factors for SA-AKI, and the novel model based on the three indicators provided a more accurate and sensitive strategy for the early prediction of SA-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.